D
David J. Heal
Researcher at University of Nottingham
Publications - 159
Citations - 5256
David J. Heal is an academic researcher from University of Nottingham. The author has contributed to research in topics: Sibutramine & Amphetamine. The author has an hindex of 36, co-authored 150 publications receiving 4893 citations. Previous affiliations of David J. Heal include BioCity Nottingham & St George's Hospital.
Papers
More filters
Journal ArticleDOI
Amphetamine, past and present--a pharmacological and clinical perspective.
TL;DR: The review charts advances in pharmaceutical development from the introduction of once-daily formulations of amphetamine through to lisdexamfetamine, which is the first d-amphetamine prodrug approved for the management of ADHD in children, adolescents and adults.
Journal ArticleDOI
Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology
Blanca Bolea-Alamanac,David J. Nutt,Marios Adamou,P. Asherson,Stephen Bazire,David Coghill,David J. Heal,Ulrich Müller,John Nash,Paramalah Santosh,Kapil Sayal,Edmund J.S. Sonuga-Barke,Susan Young +12 more
TL;DR: The present guidelines summarise current literature, generating expert consensus recommendations for the treatment of ADHD in children and adults, and provide a review of recent research in the fields of neuroimaging, neuropsychology and genetics of ADHD.
Journal ArticleDOI
The pharmacology of the behavioral and hypothermic responses of rats to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)
TL;DR: It is concluded that 8-OH-DPAT probably produces its hypothermic effects by actions at 5-HT receptors located presynaptically on5-HT neurones, while the stereotyped components of the serotonin syndrome appear to be mediated by post-synaptic receptors.
Journal ArticleDOI
Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders.
TL;DR: Comparator studies in obese animal models indicate that 5-HT6 ligands may have the potential to be more efficacious in the treatment of obesity than the current generation of anti-obesity drugs.
Journal Article
Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine.
TL;DR: The combination of these two selective monoamine reuptake inhibitors profoundly enhances thermogenesis, demonstrating a synergistic interaction of 5-HT and noradrenaline neurotransmission in the regulation of energy expenditure.